INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 5,404	$ 22,626
Short-term bank deposits	11,258	7,167
Restricted cash and short term bank deposits	542	1,076
Marketable securities	20,768	22,250
Account receivable from the Office of the Chief Scientist	180	1,691
Other account receivable	975	2,058
Total current assets	39,127	56,868
LONG-TERM ASSETS:
Long-term deposits and restricted deposits	369	361
Severance pay fund	770	753
Property and equipment, net	9,719	10,173
Total long-term assets	10,858	11,287
Total assets	49,985	68,155
CURRENT LIABILITIES
Trade payables	1,968	3,268
Accrued expenses	$ 1,157	910
Deferred revenues		379
Advance payment from United Therapeutics		93
Other accounts payable	$ 1,683	1,533
Total current liabilities	$ 4,808	6,183
LONG-TERM LIABILITIES
Deferred revenues		2,468
Accrued severance pay	$ 912	859
Other long-term liabilities	1,159	502
Total long-term liabilities	$ 2,071	$ 3,829
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Share capital: Common stock $0.00001 par value: Authorized: 200,000,000 shares Issued and outstanding: 80,079,831 shares as of March 31, 2016, 78,771,905 shares as of June 30, 2015	$ 1	$ 1
Additional paid-in capital	197,726	195,303
Accumulated deficit	$ (155,552)	(138,511)
Receivables on account of shares		(790)
Other comprehensive income	$ 931	2,140
Total stockholders' equity	43,106	58,143
Total liabilities and stockholders' equity	$ 49,985	$ 68,155